上海醫藥(02607.HK)預計上半年淨利潤增長約52%
格隆匯7月9日丨上海醫藥(02607.HK)公告,公司預計2025年上半年度實現歸屬於母公司所有者的淨利潤爲人民幣44.50億元,與上年同期相比,將增加人民幣15.08億元,同比增長約52%。
公司於2025年4月25日完成收購上海和黃藥業有限公司10%股權的交割手續,公司合計持有上海和黃股權比例從50%變更至60%,並將其納入合併報表範圍,公司對其會計覈算由合營企業的權益法覈算變更爲按子公司覈算。根據會計準則規定,因追加投資等原因能夠對非同一控制下的被投資企業實施控制的,對於購買日之前持有的被購買方的股權,應當按照該股權在購買日的公允價值進行重新計量,公允價值與其帳面價值之間的差額計入當期投資收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.